pioglitazone has been researched along with Hyperlipidemia, Familial Combined in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hyperlipidemia, Familial Combined: A type of familial lipid metabolism disorder characterized by a variable pattern of elevated plasma CHOLESTEROL and/or TRIGLYCERIDES. Multiple genes on different chromosomes may be involved, such as the major late transcription factor (UPSTREAM STIMULATORY FACTORS) on CHROMOSOME 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that pioglitazone treatment of FCH patients might increase insulin sensitivity, but may also improve serum lipid levels, body fat distribution, intramyocellular lipids (IMCL) and endothelial function." | 5.12 | Effects of pioglitazone in familial combined hyperlipidaemia. ( Abbink, EJ; De Graaf, J; De Haan, JH; Heerschap, A; Stalenhoef, AF; Tack, CJ, 2006) |
| "This study's aim was to examine whether treatment with pioglitazone, added to conventional lipid-lowering therapy, would improve myocardial glucose utilization (MGU) and blood flow (MBF) in nondiabetic patients with familial combined hyperlipidemia (FCHL)." | 5.12 | Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. ( Betteridge, J; Camici, PG; Holvoet, P; Khan, MT; Kindler, H; Leccisotti, L; Mongillo, M; Naoumova, RP; Neuwirth, C; Seed, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brouwers, MC | 1 |
| de Graaf, J | 2 |
| van Greevenbroek, MM | 1 |
| Schaper, N | 1 |
| Stehouwer, CD | 1 |
| Stalenhoef, AF | 2 |
| Abbink, EJ | 1 |
| De Haan, JH | 1 |
| Heerschap, A | 1 |
| Tack, CJ | 1 |
| Naoumova, RP | 1 |
| Kindler, H | 1 |
| Leccisotti, L | 1 |
| Mongillo, M | 1 |
| Khan, MT | 1 |
| Neuwirth, C | 1 |
| Seed, M | 1 |
| Holvoet, P | 1 |
| Betteridge, J | 1 |
| Camici, PG | 1 |
1 review available for pioglitazone and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
2 trials available for pioglitazone and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
Effects of pioglitazone in familial combined hyperlipidaemia.
Topics: Alanine Transaminase; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Humans; Hyperlip | 2006 |
Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.
Topics: Blood Glucose; Coronary Circulation; Double-Blind Method; Drug Therapy, Combination; Female; Glucose | 2007 |